Radical prostatectomy doesn't cut mortality versus observation

July 19, 2012
Radical prostatectomy doesn't cut mortality versus observation
For men with clinically localized prostate cancer, radical prostatectomy does not significantly reduce all-cause or prostate-cancer mortality compared with observation through 12 years of follow-up, according to a study published in the July 19 issue of the New England Journal of Medicine.

(HealthDay) -- For men with clinically localized prostate cancer, radical prostatectomy does not significantly reduce all-cause or prostate-cancer mortality compared with observation through 12 years of follow-up, according to a study published in the July 19 issue of the New England Journal of Medicine.

Timothy J. Wilt, M.D., M.P.H., from the University of Minnesota School of Medicine in Minneapolis, and colleagues randomly assigned 731 men with localized prostate cancer (mean age, 67 years; median prostate-specific antigen [PSA] value, 7.8 ng/mL) to radical (364 men) or observation (367 men), from November 1994 through January 2002. Patients were followed for a median of 10.0 years, through January 2010.

The researchers found that 47 and 49.9 percent, respectively, of the men in the radical prostatectomy and observation groups died (hazard ratio, 0.88; P = 0.22). Death from prostate cancer or treatment occurred for 5.8 and 8.4 percent assigned to radical prostatectomy and observation, respectively (hazard ratio, 0.63; P = 0.09). Among men with a greater than 10 ng/mL, radical prostatectomy correlated with decreased all-cause mortality (P = 0.04), and a possible decrease was seen for those with intermediate- or high-risk tumors (P = 0.07). Within 30 days after surgery 21.4 percent of men experienced adverse events, including one death.

"In conclusion, our study showed that, as compared with observation, did not significantly reduce all-cause or prostate-cancer mortality through at least 12 years among men with clinically localized prostate cancer that had been diagnosed in the era of PSA testing," the authors write.

Several authors disclosed to the pharmaceutical and medical device/technology industries; one author disclosed providing expert testimony for medical malpractice law suits.

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Recommended for you

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.